In This Article:
-
Evotec SE's (NASDAQ: EVO) subsidiary, Just - Evotec Biologics Inc, has expanded a multi-year partnership with Alpine Immune Sciences Inc (NASDAQ: ALPN) for ALPN-303 for systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases.
-
The contract is a continuation of their first-in-human program initiated in 2020, in which Just - Evotec Biologics delivered drug substance materials using their J.DESIGN continuous manufacturing platform for Alpine's ongoing Phase 1 study and anticipated Phase 2 studies of ALPN-303.
-
Related: Alpine Immune Sciences' Autoimmune Disease Candidate ALPN-303 Shows Promise in Preclinical Studies.
-
Under the expanded contract, Just - Evotec Biologics will leverage its data-driven technology platform to develop a commercial manufacturing process for ALPN-303.
-
Commercial process development activities will be performed at Just - Evotec Biologics' J.POD biomanufacturing facility in Redmond, Washington.
-
Price Action: EVO shares are down 12.7% at $12.33 during the premarket session on the last check Wednesday. ALPN stock closed at $8.49 on Tuesday.
See more from Benzinga
-
Catalent's New Acquisition will Expand High-Potent Capabilities, Oral Manufacturing Capacity: Report
-
SAB Biotherapeutics Shifts Focus On Infection Candidate As DoD Contract Closes
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.